Efficacy and safety of pioglitazone in a phase 1/2 imatinib discontinuation trial (EDI‐PIO) in chronic myeloid leukemia with deep molecular response.

Autor: Pagnano, Katia B.B., Lopes, Ana Beatriz P., Miranda, Eliana C., Delamain, Márcia T., Duarte, Gislaine O., Rodrigues, Bruna R.V., Povoa, Valquiria M.O., Furlin, Graziele C.P., Vianna, Jessica C., Silva, Matheus A.S., De Souza, Carmino A, De Paula, Erich V
Zdroj: American Journal of Hematology; Dec2020, Vol. 95 Issue 12, pE321-E323, 3p
Databáze: Complementary Index
Externí odkaz: